Clinical trials: Amyotrophic Lateral Sclerosis, open to volunteers
Healthy
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (i.e. how study drug is taken up by the body) of TBN in healthy participants.
- Trial name
- NCT04667013
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Guangzhou Magpie Pharmaceuticals Co., Ltd.
Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1)…
- Trial name
- GOALS (NCT06351592)
- Testing
- ALN-SOD, Diluent
- Where
- 22 sites in Australia, Belgium and 7 more
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals
ALS - Amyotrophic Lateral Sclerosis
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study
Following completion of the ALS Early Feasibility Study of the MyoRegulator® device for treatment of ALS (NCT06165172), the CALM study will further assess the feasibility of the MyoRegulator® device to treat ALS in an expanded…
- Trial name
- CALM (NCT06649955)
- Testing
- Multi-site direct current stimulation (DCS)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- PathMaker Neurosystems Inc.
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Tazbentetol in ALS Participants
The objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability.
- Trial name
- NCT07325591
- Testing
- Tazbentetol
- Volunteers
- 430 people
- Sponsor
- Spinogenix
Amyotrophic Lateral Sclerosis
Colchicine Effect on Amyotrophic Lateral Sclerosis Patients
The goal of this clinical trial is to evaluate whether low-dose colchicine can slow disease progression in patients with amyotrophic lateral sclerosis (ALS), a progressive and fatal neurodegenerative disorder affecting motor…
- Trial name
- CO-ALSII (NCT07813858)
- Testing
- Colchicine 0.5 MG Oral Tablet
- Where
- 5 sites in Italy
- Volunteers
- 87 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Amyotrophic Lateral Sclerosis, Adenosine Triphosphate Activities
Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis
This will be a single center, randomized, double-blind, placebo-controlled pilot study to assess the safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (mg) per os (PO) daily for patients with amyotrophic lateral…
- Trial name
- TZ-ALS (NCT07224269)
- Testing
- Terazosine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Iowa
Amyotrophic Lateral Sclerosis ALS
Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS
This is an open label trial of a supplement called HMB in patients with ALS. The researchers are evaluating its safety and tolerability, as well as its ability to lower insulin-like growth-factor binding protein 7 (IGFBP7) and…
- Trial name
- ROAR HMB (NCT07589764)
- Testing
- β-hydroxy-β-methylbutyrate (HMB)
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Duke University
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
Amyotrophic Lateral Sclerosis (ALS)
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
- Trial name
- UNITE-ALS (NCT07023835)
- Testing
- 50 mg Usnoflast, 75 mg Usnoflast
- Where
- 49 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- Zydus Therapeutics Inc.
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis)
Biofluid Research on Age-Related or Inherited Neurodegeneration
The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with…
- Conditions
- Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD)
- Trial name
- BRAIN (NCT07798700)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Amyotrophic Lateral Sclerosis
Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders
The purpose of this study is to collect, from patients with sporadic and familial ALS and their family members, clinical data and blood samples for extraction of DNA, RNA, preparation of lymphocytes, plasma and serum to establish…
- Trial name
- NCT05474235
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Amyotrophic Lateral Sclerosis
ASSESS ALL ALS Study
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control…
- Trial name
- NCT06578195
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Amyotrophic Lateral Sclerosis
PREVENT ALL ALS Study
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control…
- Trial name
- NCT06581861
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Tetraplegia, Locked-in Syndrome
Investigation on the Cortical Communication (CortiCom) System
The CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor.
- Conditions
- Tetraplegia, Locked-in Syndrome, Brainstem Stroke, Amyotrophic Lateral Sclerosis
- Trial name
- CortiCom (NCT03567213)
- Testing
- Surgical implantation of CortiCom system
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis
A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
This study will examine what happens when patients with amyotrophic lateral sclerosis (ALS) are given an investigational medication (study drug) known as LTX-002.
- Trial name
- NeurALS (NCT07660614)
- Testing
- LTX-002
- Where
- 5 sites in Germany, Italy and 2 more
- Volunteers
- 56 people
- Sponsor
- Leal Therapeutics, Inc
ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
Tongue-strengthening Exercises in People With ALS.
This study is testing a tongue exercise program for people living with ALS to see if it can help support speech and swallowing. All participants will receive the treatment, and researchers will measure changes over time by…
- Trial name
- NCT07295990
- Testing
- Isometric Lingual Strength Exercises
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nova Southeastern University
Amyotrophic Lateral Sclerosis
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood.
- Trial name
- NCT06656702
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis, Charcot Disease
Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis.
This is proof-of-concept, single-arm, single-center study to assess the safety and explore the efficacy of repeated US transient disruptions of the blood-brain barrier (BBB) in Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- Son-ALS (NCT07571486)
- Testing
- SonoCloud-4 (SC4) device
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis
Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications
The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers.
- Trial name
- NCT06266403
- Testing
- Structured Communicative Interaction, Clear Speech, Unstructured communicative interaction
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Penn State University